I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy
- 9 February 2007
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (4), 490-501
- https://doi.org/10.1177/1352458506070446
Abstract
Background Brain atrophy, as assessed by magnetic resonance imaging (MRI), has been correlated with disability in patients with multiple sclerosis (MS). Recent evidence indicates that both white matter (WM) and gray matter (GM) are subject to atrophy in patients with MS. Although neurological deficiencies in MS are primarily due to loss of WM, the clinical significance of GM atrophy has not been fully explored in MS. Methods We have undertaken a three-year, open-label study, comparing 26 patients who elected to receive intramuscular interferon beta-1a (IFN β-1a) therapy, with 28 patients who elected not to receive therapy. Both groups had quantitative cranial MRI scans at study entry and after three years, and standardized clinical assessments every six months. Brain parenchymal fraction (BPF), GM fraction (GMF), and WM fraction (WMF) percent changes were calculated, and T2- and T1-lesion volumes (LVs) assessed. Results After three years, mean percent (%) change in BPF favored the IFN β-1a treatment group (IFN β-1a —1.3% versus the control group —2.5%, P=0.009), as did the mean percent change in GMF (+0.2 versus —1.4%, P=0.014), and the mean percent change in T1-LV (—9.3 versus +91.6%, P=0.011). At the end of the study, there was a significant within-patient decrease in BPF for both groups (P=0.02 for the IFN β-1a treatment group, and P Conclusion Over a three-year period, treatment with IFN β-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group. Multiple Sclerosis 2007; 13: 490-501. http://msj.sagepub.comKeywords
This publication has 56 references indexed in Scilit:
- Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple SclerosisJournal of Neuroimaging, 2005
- Central Nervous System Atrophy and Clinical Status in Multiple SclerosisJournal of Neuroimaging, 2004
- Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosisNeuroImage, 2004
- Role of MRI in multiple sclerosis II: brain and spinal cord atrophyFrontiers in Bioscience-Landmark, 2004
- Role of MRI in multiple sclerosis I: inflammation and lesionsFrontiers in Bioscience-Landmark, 2004
- Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging StudyJournal of Neuroimaging, 2003
- Gray Matter Involvement in Multiple Sclerosis: A New Window into PathogenesisJournal of Neuroimaging, 2003
- Voxel-Based Morphometry—The MethodsNeuroImage, 2000
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983